Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Operating Leases: 2019-2025

Historic Operating Leases for Sunshine Biopharma (SBFM) over the last 3 years, with Sep 2025 value amounting to $636,708.

  • Sunshine Biopharma's Operating Leases rose 44.61% to $636,708 in Q3 2025 from the same period last year, while for Sep 2025 it was $636,708, marking a year-over-year increase of 44.61%. This contributed to the annual value of $744,724 for FY2024, which is 38.16% up from last year.
  • Latest data reveals that Sunshine Biopharma reported Operating Leases of $636,708 as of Q3 2025, which was down 9.88% from $706,530 recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's Operating Leases peaked at $744,724 during Q4 2024, and registered a low of $440,298 during Q3 2024.
  • Its 3-year average for Operating Leases is $592,276, with a median of $596,850 in 2023.
  • As far as peak fluctuations go, Sunshine Biopharma's Operating Leases fell by 22.44% in 2024, and later spiked by 52.63% in 2025.
  • Over the past 4 years, Sunshine Biopharma's Operating Leases (Quarterly) stood at $642,232 in 2022, then declined by 16.07% to $539,035 in 2023, then skyrocketed by 38.16% to $744,724 in 2024, then surged by 44.61% to $636,708 in 2025.
  • Its last three reported values are $636,708 in Q3 2025, $706,530 for Q2 2025, and $722,199 during Q1 2025.